Skip to content
    RPRX
    Earnings call· Jun 2026(Q2 FY26)

    Royalty Pharma Q2 FY26 earnings call RPRX

    Aug 5, 2026 Source

    Executive summary

    Royalty Pharma Q2 FY26 — Strong Growth and Pipeline Expansion

    Royalty Pharma delivered another quarter of strong financial performance, driven by robust portfolio receipts and effective capital allocation. The company expanded its development-stage pipeline with strategic acquisitions like cliramitug, while also raising full-year guidance. Management emphasized the long-term growth potential and the unique, irreplicable nature of its diversified royalty portfolio.

    Highlights

    5
    • Portfolio receipts grew 6% to $773 million in Q2 FY26, exceeding expectations.

    • Total receipts, representing recurring cash flows, increased by 14% in Q2 FY26.

    • Return on invested capital was 14.2% and return on invested equity was 20.1% for the LTM ending Q2 FY26.

    • Deployed $1.1 billion of capital on royalty acquisitions year-to-date FY26, with an announced value of $1.7 billion.

    • Full-year 2026 portfolio receipts guidance raised to $3.4 billion-$3.5 billion, up from $3.325 billion-$3.45 billion.

    Concerns

    3
    • Milestones and other contractual receipts declined substantially in Q2 FY26 due to a prior-year one-time payment.

    • The portfolio absorbed significant headwinds from Promacta's loss of exclusivity and the launch of biosimilar TYSABRI in the US.

    • Milestones and other contractual receipts are expected to decrease from $128 million in 2025 to approximately $60 million in 2026.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year 2026 Portfolio Receipts
    $3.4B to $3.5B
    high materiality
    High
    Full-year 2026 Royalty Receipts Growth
    7% to 10%
    high materiality
    High
    Full-year 2026 Operating and Professional Costs
    5.5% to 6.5% of portfolio receipts
    medium materiality
    High
    Full-year 2026 Interest Paid
    ~$350M to $360M
    medium materiality
    High
    Milestones and Other Contractual Receipts
    ~$60M
    medium materiality
    High
    Cliramitug Peak Annual Sales
    $3B to $5B
    high materiality
    Medium
    Cliramitug Peak Annual Royalties
    ~$110M to $190M
    high materiality
    Medium
    Long-term Portfolio Receipts
    $4.7B or more
    high materiality
    High

    Operational metrics

    26
    Return on Invested Capital
    14.2%
    LTM Q2 FY26

    Demonstrates attractive returns.

    Return on Invested Equity
    20.1%
    LTM Q2 FY26

    Shows impact of conservative leverage on equity returns.

    Operating and Professional Costs as % of Portfolio Receipts
    4.8%
    Q2 FY26

    Demonstrates benefit of cash savings from internalization transaction.

    Portfolio Cash Flow (Adjusted EBITDA less Net Interest Paid)
    $736M
    Q2 FY26

    Represents cash generated by the business for redeployment.

    Cash Conversion Margin
    ~95%
    Q2 FY26

    High underlying level of cash conversion and efficiency.

    Weighted Average Share Count Decline
    5M shares1% YoY
    Q2 FY26

    Reflecting impact of share buyback program.

    Cash and Equivalents
    $812M
    as of June 30, 2026

    Balance at quarter end.

    Investment Grade Debt Outstanding
    $9.2B
    as of June 30, 2026

    Long-term debt profile.

    Leverage (Total Debt to Adjusted EBITDA)
    2.8x
    as of June 30, 2026

    Leverage on a total debt basis.

    Leverage (Net Debt to Adjusted EBITDA)
    2.6x
    as of June 30, 2026

    Leverage on a net debt basis.

    Undrawn Revolver Capacity
    $1.8B
    as of June 30, 2026

    Available liquidity.

    Financial Flexibility
    >$4B
    Current

    Total financial capacity.

    Capital Deployed on Royalty Deals
    $877M
    H1 FY26

    Investment in attractive royalty deals.

    Shareholder Returns (Dividends & Buybacks)
    $367M
    H1 FY26

    Includes share repurchases.

    Portfolio Cash Flow Returned to Shareholders
    ~25%
    YTD FY26

    Percentage of portfolio cash flow returned to shareholders.

    Interest Paid
    ~$175M
    Q3 FY26

    Anticipated interest payment for the quarter.

    Interest Paid
    de minimis
    Q4 FY26

    Anticipated interest payment for the quarter.

    Interest Received on Cash Balance
    $11M
    H1 FY26

    Interest income from cash balance.

    Development Stage Pipeline Growth (Therapies)
    19from 3 at IPO (June 2020)
    Current

    Significant expansion of the development stage pipeline.

    Development Stage Pipeline Peak Royalty Potential
    ~$2Bincreased >30-fold since IPO
    Current

    Peak potential royalties from late-stage pipeline.

    Development Stage Investment Regulatory Approval Success Rate
    ~90%
    Historical

    Track record of successful regulatory approvals for development-stage investments.

    Invested Capital at Work
    $22B
    Current

    Total invested capital, with a breakdown between approved and development-stage products.

    Development Stage Capital at Work
    12%
    Current

    Portion of total invested capital in development-stage therapies, with a significant portion having positive pivotal results.

    Synthetic Royalty Market Growth Rate
    ~40%
    since 2015

    Growth rate of the synthetic royalty marketplace.

    Synthetic Royalty Capital Raised (Last Year)
    just under $5B
    Last year

    Largest year ever for synthetic royalty capital raised.

    Synthetic Royalty Opportunity as % of Biopharma Funding
    ~5%
    Last 5 years

    Indicates underpenetration of the synthetic royalty market in overall biopharma funding.

    Industry KPIs

    7
    MetricValueDetails
    Peak sales guidance$3B to $5BUSD
    EPS revenue guidance$3.4B to $3.5BUSD
    Pricing policy impactPotential impact
    Pipeline clinical milestones19therapies
    Regulatory approvals filingsMultipleapprovals
    Clinical trial efficacy safety dataPositive
    Business development capacity deal appetite>$4BUSD

    Deals & partnerships

    1
    Neurimmune / AstraZenecaAcquisition of a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug.up to $425M

    Transaction included $125M upfront payment to Neurimmune, an additional $125M payment in Q1 2027, and up to $175M payable on key clinical and regulatory milestones.

    Risks & headwinds

    4
    Loss of exclusivity for PromactaQ2 FY26

    Significant headwind

    Mitigation: Absorbed by strong performance of diversified portfolio.

    Launch of biosimilar TYSABRI in the United StatesQ2 FY26

    Significant headwind

    Mitigation: Absorbed by strong performance of diversified portfolio.

    Potential impact of IRAFY26

    Considered in guidance

    Mitigation: Guidance takes into account potential impact.

    US policy risk (Coins Act, Ben's Act) on China marketOngoing

    Not quantified, too early to comment on specifics

    Mitigation: Monitoring closely, committed to China opportunity, local presence, existing royalty agreements in place, royalties are different from equity.

    What to watch in Q3 FY26

    4

    Pelacarsen Lp(a) outcomes trial results

    2026
    CurrentResults expected 2026
    TargetPositive clinical data / MACE risk reduction

    Why it matters

    This is the first outcomes study for an Lp(a) lowering therapy, potentially opening a new major class of cardiovascular drugs and validating Royalty Pharma's investment in this area.

    In 2026, we expect to see the results of the outcomes trial for Novartis' pelacarsen. We continue to believe that the Lp(a) class could be the next major class of cardiovascular disease drugs, and we're strongly positioned to leverage this with the 2 lead pipeline products in pelacarsen and Amgen's olpasiran.

    Q&A highlights

    8

    How does increased pharma M&A affect deal structure flexibility (equity vs. debt)? Does the improved credit rating or potential rate decreases bias more capital deployment?

    Royalty Pharma has significant financial flexibility to partner in M&A opportunities. The company is agnostic to the rate environment, having deployed capital successfully in both rising and falling rate scenarios, focusing on generating returns in excess of its cost of capital while maintaining its investment-grade rating.

    we truly are agnostic to the rate environment. Rates over a couple of years were rising. We deployed a lot of capital, generated great returns in excess of our cost of capital. to the extent that rates start going down, we still feel like we can deploy capital and generate great returns.

    asked by Geoffrey Meacham · answered by Terrance Coyne

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Financial Performance and Capital Allocation

    Royalty Pharma reported a strong second quarter with portfolio receipts growing 6% to $773 million, surpassing expectations. Total recurring cash flows increased by 14%. The company maintained attractive returns, with a 14.2% return on invested capital and a 20.1% return on invested equity for the last twelve months. Capital deployment for royalty acquisitions reached $1.1 billion year-to-date, alongside returning approximately $370 million to shareholders through dividends and share repurchases in the first half of the year.

    02

    Strategic Portfolio Expansion and Pipeline Success

    The company continued to expand its diversified portfolio, notably acquiring a royalty on AstraZeneca's cliramitug, a potential blockbuster therapy for ATTR-CM. This marks Royalty Pharma's second investment in TTR amyloidosis, leveraging deep therapeutic expertise. The development-stage pipeline has grown significantly, from 3 therapies at IPO to 19 today, with its peak royalty potential increasing over 30-fold to approximately $2 billion. The company boasts a 90% success rate for regulatory approval of its development-stage investments.

    03

    Cliramitug Acquisition and ATTR-CM Market Opportunity

    The acquisition of a 3.75% royalty on cliramitug for up to $425 million strengthens Royalty Pharma's position in the ATTR-CM market, which exceeded $7 billion last year. Cliramitug, a first-in-class TTR fibril depleting antibody, is designed to remove amyloid and potentially reverse disease progression, offering a differentiated approach compared to existing therapies like Amvuttra (also in Royalty Pharma's portfolio). AstraZeneca projects peak annual sales for cliramitug between $3 billion and $5 billion, translating to $110 million to $190 million in peak annual royalties.

    04

    Future Catalysts from Development Stage Pipeline

    Royalty Pharma anticipates several major pivotal trial readouts through 2027. Key events in 2026 include results from Novartis' pelacarsen outcomes trial for Lp(a) and Biogen's litifilimab Phase III data in systemic lupus. In 2027, expected readouts include daraxonrasib in lung cancer, litufilimab in cutaneous lupus, Sanofi's frexalimab in MS, and J&J's seltorexant in major depressive disorder. These therapies are expected to significantly contribute to future top-line growth.

    05

    China Market Opportunity and Strategy

    Royalty Pharma views China as a significant long-term opportunity, driven by the country's innovation and the need for U.S. and European partners for clinical trials and commercialization. The company is taking a patient approach, building its presence and educating the market. Deals in China typically involve offshore entities and contracts governed by U.S. or European law, similar to existing royalty transactions, mitigating some policy risks associated with equity investments.

    06

    Competitive Moat and Barriers to Entry

    CEO Pablo Legorreta emphasized the irreplicable nature of Royalty Pharma's business model, citing significant barriers to entry. These include the company's scale ($22 billion invested capital), low cost of capital, and a superb, experienced team. Crucially, the portfolio comprises unique, one-of-a-kind assets like royalties on TREMFYA, Trelegy, and cystic fibrosis drugs, which took decades to assemble and cannot be spontaneously recreated, even with substantial capital.

    AI-generated summary of the company’s earnings call. Not investment advice.